In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among the available covalent BTK inhibitors Preferred partner anti-CD20 antibody in CLL/SLL Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL Use of CAR T-cell therapy in CLL/SLL Presenters: Farrukh Awan, MD Professor of Internal Medicine Director of Lymphoid Malignancies Program Harold C. Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center Dallas, Texas Jeremy S. Abramson, MD, MMSc Director, Center for Lymphoma Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Shuo Ma, MD, PhD Professor of Medicine Division of Hematology-Oncology Department of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, Illinois Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie. Link to full program: https://bit.ly/3LzA2As Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
